{Taj Pharma Report} Lung cancer mortality expected to decrease over the next half century
“Tobacco control efforts implemented since the 1960s will continue to reduce lung cancer rates well into the next half-century. Additional prevention and cessation efforts will be required to sustain and expand these gains to further reduce the lung cancer burden in the United States”: this is the conclusion of a study just published in the Annals of Internal Medicineby Rafael Meza, Associate Professor of Epidemiology at the University of Michigan, and colleagues from the Cancer Intervention and Surveillance Modeling Network (CISNET) lung cancer consortium at Georgetown University, the Massachusetts General Hospital, Harvard Medical School, the University of Michigan, and Yale University.
They used four independent models based on data on smoking from 1964 to 2015 and lung cancer mortality data from 1969 to 2010, and estimated that in the near future age-adjusted lung cancer mortality in the United States could drop by 79%, falling from 135,000 in 2015 to 50,000 in 2065. Annual lung cancer deaths could also decrease by 63% over the same period
With current trends, by 2065, around 20 million men and women (aged 30 – 84 years) will still be smoking, and 4.4 million Americans could die from lung cancer. “Continued policies and measures to discourage the uptake of smoking in youth and to promote cessation among current users are thus needed to retain the gains that have already been made, with additional efforts required to further decrease the toll of tobacco smoking on health,” researchers wrote. According to their prediction, smoking prevalence will decrease from 19.7% in 2015 (21.6% in men and 17.8% in women) to 7.5% in 2065 (8.9% in men and 6.0% in women) and by the mid-2040s, lung cancer rates by sex will be almost equal: “This reflects the convergence in smoking behaviors between men and women as current cohorts with similar smoking patterns by sex become the bulk of the smoking population” the researchers commented. However, “Cancer deaths among never-smokers are projected to increase due to population growth and an increase in the proportion of people who have never smoked,” said Meza.
Lung cancer will remain the number one cause of cancer death globally, and therefore smoking will continue to be an important determinant of risk and a major public health problem. E-cigarettes or polytobacco usage effect on smoking prevalence were not considered in Meza’s article, as well as the potential impact of lung screening, but if adopted could additionally decrease lung cancer mortality overall, according to the authors.
About – Taj Oncology
Taj Oncology’s vision is to become a world class player in oncology through excellence in innovation, discovery of new manufacturing processes / drug delivery mechanisms and consistently high quality of production.
We commenced operations in 1994 with the inauguration of our ultra-modern facility for the production of generics and formulations for oncology and other therapeutic applications. We are one of the pioneers in India in lyophilization.
We identified, very early, the need for achieving self – sufficiency in formulations as well as in Active Pharmaceutical Ingredients (APIs) , and our achievements reflect this focus. We launched our (APIs) in year 1994 & now have to our credit a number of new manufacturing processes & drug delivery mechanisms.
We have a manufacturing plant located at Tarapur, Thane in Maharashtra State. This facility meets the current Good Manufacturing Practices norms as laid down by the World Health Organization.
Our marketing spans domestic and overseas operations. With a network across the Indian sub-continent and market penetration in several countries across four continents, we are on our way to meeting our target of reaching out to cancer patients, worldwide.
Taj Pharmaceuticals, is a generics pharmaceuticals company with product range exceeding 4600 compositions under all therapeutic categories
Taj Pharmaceuticals Limited manufactures and distributes medicines. The company’s products include prescription solutions, lifesaving drugs, anti-cancer drugs, veterinary products, consumer brands, and CNS drugs. It focuses on medicines of anemia, anxiety disorders, cancer/oncology, ear infections, heart failure, hepatitis, HIV/AIDS, influenza, non-Hodgkin’s lymphoma, obesity, osteoporosis, Parkinson’s disease, pneumonia, transplantation, and common diseases. Taj Pharmaceuticals India Business is headquartered in Mumbai, India.
Taj Pharmaceuticals is the global leader in generics and one of the India’s top ten pharmaceutical companies. Taj Pharma India play a leading role in therapeutic areas such as cancer, virology and transplantation. The combined strengths of Taj Pharma generics and pharmaceuticals businesses, coupled with expertise in the emerging genetic sciences, equip us to develop integrated healthcare solutions and therapeutic approaches tailored to individual patients’ needs. Taj Pharmaceutical’s products and services address the entire healthcare spectrum, from screening for genetic risk factors, to preventing, diagnosing and treating disease, and monitoring the treatment response.
Taj Pharma India delivers a unique contribution to better healthcare. Taj Pharma India aim to reduce suffering and improve health and quality of life of people all around the world. At Taj Pharmaceuticals, Taj Pharma India have pursued this mission with patience, dedication, imagination and skill, for over a century. Taj Pharma vision is to develop targeted medicines and diagnostic tools that combine to offer patients, physicians and payers better, safer, more cost-effective healthcare.
Once again, welcome to Taj Pharmaceuticals, a great company that is translating a great vision into reality – We Innovate Generics Healthcare.
Taj Pharmaceuticals Limited is committed to earning the trust of doctors, patients and customers every day. Taj Pharma colleagues worldwide believe that trust is not easily granted, and that is the reason Taj Pharma India focus each day on becoming a champion for Taj Pharma stakeholders.
During the past ten years, Taj Pharmaceuticals Group has been building a new kind of health care company. Throughout Taj Pharma Group (India), there’s a desire to build long-term relationships with Taj Pharma stakeholders based on mutual confidence. This is evident in many ways. Taj Pharma scientists are earning trust through the discovery and development of innovative, science-based medicines and services that improve the health and overall well-being of people around the world. Taj Pharma sales professionals, marketing teams, colleagues working at Taj Pharma plants and others throughout the organization at all levels of responsibility take each day as a fresh opportunity to earn trust.
All of this takes hard work, sharp execution, integrity and transparency on the part of Taj Pharmaceuticals Group colleagues. Taj Pharma global team is working to sustain and expand innovative new treatments. Taj Pharma India’re determined to do Taj Pharma part to increase access to better health care for all people. And, Taj Pharma India is focused on becoming the best in three key strategic areas: people, products and processes.
Taj Pharma India’re beginning to see the results of Taj Pharma efforts, but believe the best is yet to come. The test of being a true champion is to never give up and to passionately strive for even better outcomes. From Taj Pharma perspective as a health care company, that means helping people around the world live better and live longer.The product range includes major generic drugs under therapeutic category such as anti-cancer drugs, CNS drugs; Key category of products includes generic medicines for anemia, anxiety disorders, cancer/oncology, ear infections, heart failure, hepatitis, HIV/AIDS, influenza, non-Hodgkin’s lymphoma, obesity, osteoporosis, Parkinson’s disease, pneumonia, transplantation and common diseases.
